{
  "docId": "019de073-79f3-7749-b6d9-2feecaaa4d92",
  "docSlug": "3bbd721bd246637706dab09d5c4f3165",
  "documentTitle": "Apexigen | Investor Presentation Deck | 27 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 27,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a three-column structure to summarize the company's value proposition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-79f3-7749-b6d9-2feecaaa4d92/3",
  "deckHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92",
  "deckJsonHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92.json",
  "deckAnchorHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.52,
        "x": 0.24,
        "y": 0.073
      },
      "kind": "callout",
      "text": "UNIQUE APXiMAB™ ANTIBODY DISCOVERY PLATFORM",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dad1be76-8bd3-4f90-ad22-1293daa87794",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.82,
        "x": 0.09,
        "y": 0.35
      },
      "kind": "list",
      "text": "LEAD PRODUCT: Sotigalimab/APX005M. Potentially first-in-class and best-in-class CD40 agonist with clinical immune-priming and efficacy data. PROPRIETARY PIPELINE: Pipeline of Candidates. APX601 TNFR2 (IND ready), APX801 NK cell engager, Additional research programs. VALIDATING PARTNERSHIPS: 5 Licensees. Apexigen receiving Royalties on sales of Novartis' Beovu product.",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fce27ba6-6744-4ac4-acdb-842f61dda9b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "title",
      "text": "Leader in Discovering and Developing Innovative Therapeutic Antibodies Against Cancer",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c06e94c9-82b7-4c86-ad3c-79b328e30322",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.26,
        "x": 0.37,
        "y": 0.12
      },
      "kind": "title",
      "text": "Apexigen",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47991b83-683e-4618-befe-7ffa1d5558e2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "b8c87c18-225e-418c-8726-82c7bb8eb11c",
      "evidence": "This slide is labeled as 'executive_summary'.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "78d6a8df-6efc-40db-93fc-ce9f8bc4283c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 3-5 present an overview of the current state of cancer treatment and the need for innovative solutions",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "da168929-7490-4525-afaf-0185eb5bfe52",
      "evidence": "The problem section implies that the cost of inaction is high",
      "position": 0,
      "objective": "What is the cost of not investing in innovative cancer treatments?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}